Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AuricX

2006 FOUNDED
PRIVATE STATUS
Grant LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of treatments for Methicillin Resistant Staphylococcus Aureus. The company provides anti-infectives to treat infections arising from strains of Staphylococcus Aureus and other difficult to treat pathogens. It has developed BPH-652, a clinical trial-stage small molecule that has been shown to be effective against multiple strains of Staphylococcus Aureus (S. aureus) in animal models.

Website
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 3400 Research Forest Drive
  • Suite B4
  • The Woodlands, TX 77380
  • United States

+1 (281) 000-0000

AuricX Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore AuricX‘s full profile, request access.

Request full access to PitchBook

AuricX Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore AuricX‘s full profile, request access.

Request full access to PitchBook

AuricX Executive Team (1)

Name Title Board
Seat
Contact
Info
Timothy Madden MD Chief Executive Officer & President

AuricX Board Members (3)

Name Representing Role Since Contact
Info
0000 00000000 00.0 AuricX Co-Chairman & Member of Scientific Advisory Board 000 0000
000000 000 00.0 AuricX Member of Scientific Advisory Board 000 0000
000000 00000 00 AuricX Co-Founder & Chairman, Scientific Advisory Board 000 0000